Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia

Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemilumines...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of alzheimer's disease 2011, Vol.2011 (2011), p.1-9
Hauptverfasser: Spitzer, Philipp, Schieb, Heinke, Kamrowski-Kruck, Heike, Otto, Markus, Chiasserini, Davide, Parnetti, Lucilla, Herukka, Sanna-Kaisa, Schuchhardt, Johannes, Wiltfang, Jens G., Klafki, Hans-Wolfgang
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 9
container_issue 2011
container_start_page 1
container_title International journal of alzheimer's disease
container_volume 2011
creator Spitzer, Philipp
Schieb, Heinke
Kamrowski-Kruck, Heike
Otto, Markus
Chiasserini, Davide
Parnetti, Lucilla
Herukka, Sanna-Kaisa
Schuchhardt, Johannes
Wiltfang, Jens G.
Klafki, Hans-Wolfgang
description Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau), phosphorylated Tau (pTau), and beta-amyloid 42 peptide (Aβ42). CSF-ERK1/2 was significantly increased in the AD group as compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal fluid sample revealed that both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and Aβ42.
format Article
fullrecord <record><control><sourceid>emarefa</sourceid><recordid>TN_cdi_emarefa_primary_494893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>494893</sourcerecordid><originalsourceid>FETCH-emarefa_primary_4948933</originalsourceid><addsrcrecordid>eNqFidEKgjAUQEcUJOUnBPcHpDWV3GPYJKheondZeaUbc8pmQn19Bb13Xs6BM2KB4JJHXKRi_OuMi2TKQu_v_MuapzIL2FENVKG9ItStA2Vw0D1WkKPDi2t9R1YbKMyDKlCn_Wop4IADGg9kYWNeN6QGHWyxQduTnrNJrY3H8OcZWxTqnO8ibLTDWpedo089y0QmmYzjf_8NdOw6lA</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Spitzer, Philipp ; Schieb, Heinke ; Kamrowski-Kruck, Heike ; Otto, Markus ; Chiasserini, Davide ; Parnetti, Lucilla ; Herukka, Sanna-Kaisa ; Schuchhardt, Johannes ; Wiltfang, Jens G. ; Klafki, Hans-Wolfgang</creator><creatorcontrib>Spitzer, Philipp ; Schieb, Heinke ; Kamrowski-Kruck, Heike ; Otto, Markus ; Chiasserini, Davide ; Parnetti, Lucilla ; Herukka, Sanna-Kaisa ; Schuchhardt, Johannes ; Wiltfang, Jens G. ; Klafki, Hans-Wolfgang</creatorcontrib><description>Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau), phosphorylated Tau (pTau), and beta-amyloid 42 peptide (Aβ42). CSF-ERK1/2 was significantly increased in the AD group as compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal fluid sample revealed that both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and Aβ42.</description><identifier>ISSN: 2090-8024</identifier><identifier>EISSN: 2090-0252</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Puplishing Corporation</publisher><ispartof>International journal of alzheimer's disease, 2011, Vol.2011 (2011), p.1-9</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Spitzer, Philipp</creatorcontrib><creatorcontrib>Schieb, Heinke</creatorcontrib><creatorcontrib>Kamrowski-Kruck, Heike</creatorcontrib><creatorcontrib>Otto, Markus</creatorcontrib><creatorcontrib>Chiasserini, Davide</creatorcontrib><creatorcontrib>Parnetti, Lucilla</creatorcontrib><creatorcontrib>Herukka, Sanna-Kaisa</creatorcontrib><creatorcontrib>Schuchhardt, Johannes</creatorcontrib><creatorcontrib>Wiltfang, Jens G.</creatorcontrib><creatorcontrib>Klafki, Hans-Wolfgang</creatorcontrib><title>Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia</title><title>International journal of alzheimer's disease</title><description>Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau), phosphorylated Tau (pTau), and beta-amyloid 42 peptide (Aβ42). CSF-ERK1/2 was significantly increased in the AD group as compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal fluid sample revealed that both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and Aβ42.</description><issn>2090-8024</issn><issn>2090-0252</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFidEKgjAUQEcUJOUnBPcHpDWV3GPYJKheondZeaUbc8pmQn19Bb13Xs6BM2KB4JJHXKRi_OuMi2TKQu_v_MuapzIL2FENVKG9ItStA2Vw0D1WkKPDi2t9R1YbKMyDKlCn_Wop4IADGg9kYWNeN6QGHWyxQduTnrNJrY3H8OcZWxTqnO8ibLTDWpedo089y0QmmYzjf_8NdOw6lA</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Spitzer, Philipp</creator><creator>Schieb, Heinke</creator><creator>Kamrowski-Kruck, Heike</creator><creator>Otto, Markus</creator><creator>Chiasserini, Davide</creator><creator>Parnetti, Lucilla</creator><creator>Herukka, Sanna-Kaisa</creator><creator>Schuchhardt, Johannes</creator><creator>Wiltfang, Jens G.</creator><creator>Klafki, Hans-Wolfgang</creator><general>Hindawi Puplishing Corporation</general><scope>ADJCN</scope><scope>AHFXO</scope></search><sort><creationdate>2011</creationdate><title>Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia</title><author>Spitzer, Philipp ; Schieb, Heinke ; Kamrowski-Kruck, Heike ; Otto, Markus ; Chiasserini, Davide ; Parnetti, Lucilla ; Herukka, Sanna-Kaisa ; Schuchhardt, Johannes ; Wiltfang, Jens G. ; Klafki, Hans-Wolfgang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-emarefa_primary_4948933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spitzer, Philipp</creatorcontrib><creatorcontrib>Schieb, Heinke</creatorcontrib><creatorcontrib>Kamrowski-Kruck, Heike</creatorcontrib><creatorcontrib>Otto, Markus</creatorcontrib><creatorcontrib>Chiasserini, Davide</creatorcontrib><creatorcontrib>Parnetti, Lucilla</creatorcontrib><creatorcontrib>Herukka, Sanna-Kaisa</creatorcontrib><creatorcontrib>Schuchhardt, Johannes</creatorcontrib><creatorcontrib>Wiltfang, Jens G.</creatorcontrib><creatorcontrib>Klafki, Hans-Wolfgang</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><jtitle>International journal of alzheimer's disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spitzer, Philipp</au><au>Schieb, Heinke</au><au>Kamrowski-Kruck, Heike</au><au>Otto, Markus</au><au>Chiasserini, Davide</au><au>Parnetti, Lucilla</au><au>Herukka, Sanna-Kaisa</au><au>Schuchhardt, Johannes</au><au>Wiltfang, Jens G.</au><au>Klafki, Hans-Wolfgang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia</atitle><jtitle>International journal of alzheimer's disease</jtitle><date>2011</date><risdate>2011</risdate><volume>2011</volume><issue>2011</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>2090-8024</issn><eissn>2090-0252</eissn><abstract>Cerebrospinal fluid (CSF) samples from 33 patients with Alzheimer dementia (AD), 21 patients with mild cognitive impairment who converted to AD during followup (MCI-AD), 25 patients with stable mild cognitive impairment (MCI-stable), and 16 nondemented subjects (ND) were analyzed with a chemiluminescence immunoassay to assess the levels of the mitogen-activated protein kinase ERK1/2 (extracellular signal-regulated kinase 1/2). The results were evaluated in relation to total Tau (tTau), phosphorylated Tau (pTau), and beta-amyloid 42 peptide (Aβ42). CSF-ERK1/2 was significantly increased in the AD group as compared to stable MCI patients and the ND group. Western blot analysis of a pooled cerebrospinal fluid sample revealed that both isoforms, ERK1 and ERK2, and low amounts of doubly phosphorylated ERK2 were detectable. As a predictive diagnostic AD biomarker, CSF-ERK1/2 was inferior to tTau, pTau, and Aβ42.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Puplishing Corporation</pub><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2090-8024
ispartof International journal of alzheimer's disease, 2011, Vol.2011 (2011), p.1-9
issn 2090-8024
2090-0252
language eng
recordid cdi_emarefa_primary_494893
source EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access
title Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T19%3A49%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-emarefa&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evidence%20for%20Elevated%20Cerebrospinal%20Fluid%20ERK1/2%20Levels%20in%20Alzheimer%20Dementia&rft.jtitle=International%20journal%20of%20alzheimer's%20disease&rft.au=Spitzer,%20Philipp&rft.date=2011&rft.volume=2011&rft.issue=2011&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=2090-8024&rft.eissn=2090-0252&rft_id=info:doi/&rft_dat=%3Cemarefa%3E494893%3C/emarefa%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true